About: Secondary Bacterial Infections in Patients With Viral Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secondary Bacterial Infections in Patients With Viral Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Secondary Bacterial Infections in Patients With Viral Pneumonia
Creator	Hua, X Leptihn, S Loh, B Manohar, P Nachimuthu, R Sc, Welburn
Source	Medline; PMC
abstract	Pulmonary diseases of viral origin are often followed by the manifestation of secondary infections, leading to further clinical complications and negative disease outcomes. Thus, research on secondary infections is essential. Here, we review clinical data of secondary bacterial infections developed after the onset of pulmonary viral infections. We review the most recent clinical data and current knowledge of secondary bacterial infections and their treatment in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied respiratory virus, influenza, are described. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This evaluation includes recent clinical reports of pulmonary viral infections, including those by COVID-19, that reference secondary infections. Where data was provided for COVID-19 patients, a mortality rate of 15.2% due to secondary bacterial infections was observed for patients with pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2 infections with prophylactic antibiotics (63.7%, n = 1,901), compared to 73.5% (n = 3,072) in all clinical reports of viral pneumonia included in this review. For all cases of viral pneumonia, a mortality rate of 10.9% due to secondary infections was observed (53 of 482). Most commonly, quinolones, cephalosporins and macrolides were administered, but also the glycopeptide vancomycin. Several bacterial pathogens appear to be prevalent as causative agents of secondary infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae.
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.3389/fmed.2020.00420
bibo:pmid	32850912
has license	cc-by
sha1sum (hex)	536b02b8710cd268444f1d0272682ec96eb0300c
schema:url	https://doi.org/10.3389/fmed.2020.00420
resource representing a document's title	Secondary Bacterial Infections in Patients With Viral Pneumonia
has PubMed Central identifier	PMC7419580
has PubMed identifier	32850912
schema:publication	Front Med (Lausanne)
resource representing a document's body	covid:536b02b8710cd268444f1d0272682ec96eb0300c#body_text
is schema:about of	named entity 'COVID-19' named entity 'infections' named entity 'Pulmonary diseases' named entity 'influenza' named entity 'respiratory' named entity 'data' named entity 'OUTLINE' named entity 'NEGATIVE' named entity 'SARS-COV' named entity 'KNOWLEDGE' named entity 'CEPHALOSPORINS' named entity 'CAUSATIVE AGENTS' named entity 'RESPIRATORY VIRUS' named entity 'ORIGIN' named entity 'VANCOMYCIN' named entity 'QUINOLONES' named entity 'PREVALENT' named entity 'CLINICAL' named entity 'BACTERIAL INFECTIONS' named entity 'STRAINS' named entity 'INFLUENZA' named entity 'COVID-19' named entity 'REVIEW' named entity 'GLYCOPEPTIDE' named entity 'MOST RECENT' named entity 'CASES' named entity 'virus' named entity 'viral pneumonia' named entity 'vancomycin' named entity 'clinicians' named entity 'strains' named entity 'This' named entity 'infections' named entity 'patients' named entity 'observed' named entity 'compared' named entity 'negative' named entity 'patients' named entity 'secondary' named entity 'MERS-CoV' named entity 'bacterial pathogens' named entity 'manifestation' named entity 'quinolones' named entity 'pneumonia' named entity 'secondary' named entity 'prophylactic antibiotics' named entity 'Klebsiella pneumoniae' named entity 'quinolones' named entity 'MERS-CoV' named entity 'COVID-19' named entity 'positive' named entity 'pathogens' named entity 'host-pathogen interactions' named entity 'S. aureus' named entity 'Center for Disease Control and Prevention' named entity 'secondary bacterial infections' named entity 'vancomycin' named entity 'bacterial viruses' named entity 'secondary bacterial infections' named entity 'antibiotics' named entity 'prophylactic' named entity 'P. aeruginosa' named entity 'respiratory syncytial virus' named entity 'June 2012' named entity '2, 3' named entity 'prophylactic' named entity 'secondary bacterial infections' named entity 'RSV' named entity 'SARS-CoV-2' named entity 'viral replication' named entity 'carbapenem' named entity 'pathogenic bacterium' named entity 'vancomycin' named entity 'antibiotic' named entity 'cefepime' named entity 'immune response'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software